A recent systematic review looked at the current state of precision oncology for patients with endometrial, ovarian, and cervical carcinomas. The analysis focused on how molecular classifications and biomarker-guided therapies are being used compared to older methods based only on tissue appearance. The review included data on drugs like PARP inhibitors, immune checkpoint inhibitors, and antibody-drug conjugates such as mirvetuximab soravtansine and tisotumab vedotin.
The main finding was that reclassifying tumors by their molecular makeup has allowed doctors to use targeted agents more effectively. For example, PARP inhibitors work well for ovarian cancers with specific DNA repair defects, while immune checkpoint inhibitors help some endometrial and cervical cancers. These advances represent a significant shift toward personalized care in gynecologic oncology.
Despite these successes, the review highlights a critical challenge: acquired resistance. As tumors evolve and become more complex, they can stop responding to these powerful new therapies. This barrier to long-term control is driven by the natural changes within cancer cells. Readers should understand that while these tools are promising, they are not a complete solution yet. Future progress will depend on new diagnostics, better drugs, and smarter clinical trial designs to overcome this resistance.
